title: A review of phase II acute heart failure syndromes clinical trials.
abstract: Hospitalization for acute heart failure syndromes (AHFS) is a growing health care burden. Over 1 million hospitalizations occur annually, with a postdischarge mortality and rehospitalization rate of ~45% by 90 days and a financial cost greater than $20 billion. Attempts to improve outcomes through novel therapies have largely failed, suggesting new approaches are needed. We review phase II studies in AHFS to identify opportunities for future development programs.
authors.affiliation: Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, 211 East Ontario Street, Chicago, IL 60611, USA. ppang@northwestern.edu
authors.forename: Peter S
authors.initials: PS
authors.lastname: Pang
authors.forename: Mihai
authors.initials: M
authors.lastname: Gheorghiade
mesh_terms: D000208:Acute Disease; D058406:Cardiac Resynchronization Therapy / Q000379:methods*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D013577:Syndrome
chemical_list: D002317:Cardiovascular Agents